| Notices |
Welcome to the latest in bloodless medicine and blood transfusion alternatives.
We are a community of medical professionals and members of the public who are responding to the worldwide concern about the efficacy, cost and availability of donor blood. |
noblood Home 
Forums 
| What's Going On? | |
Currently Active Users: 44 (1 members and 43 guests)
|
|
 |
Most users ever online was 247, 05-29-2008 at 12:33 PM.
|
|
Users active in the past 48 hours: 2274 (49 members and 2225 guests)
|
|
|
|
aap2, AlexMillerRN, Bob Jordan, BVAGUY, Cynthia, davidgrist, dgporkchop, Donal, efgh531, ekgRN, Felicia, feliciajohnson6, finnkina, hilda75, I. N. Usoro, Informaticus, jgrossberg, jimclh, jin hwa park, Jose, jtmorete, Ken McGuire, ksamolyk, LarryEitel, lcaincpc, legalsimon, Leslie Richards, lori-carlson, lswilson, lyndaprem, markeldredge, MaryGhiglioneRN, MColumbus, melissa_m_loyd, mharty, Morninglory51, NW Sukosky RN, osvaglez, Richard Casas, Richard Morian, Rob R., rvigiltmspcoord, Sally, Sharon Grant, sybilleruth, Tim Hughes, tony pad, twins2teens, warrenbehr
|
| Physicians - Nurses - Healthcare Professionals - Moderators - Administrators | |
|
These are the 49 most used thread tags
|
|
 |
aids anemia aprotinin autologous blood donation bleeding blood blood conservation techniques blood fractions blood substitutes burns cancer cardiac cell chemotherapy clinical conservation cryoprecipitate dialysis epo erythropoietin erythropoietin (epo) factor viia gynecology obstetrics heart disease hemophilia hepatitis hospitals hypertension infection iron leukemia liver management minimally invasive procedures oxygenation pediatric perioperative pregnancy program recombinant safety sickle cell (scd) stem cell therapy stroke surgery thrombocytopenia transfusion transfusions transplant |
|
noblood Statistics
|
|
|
Threads: 3,885,
Posts: 9,106,
Members: 9,925,
Active Members: 75
Welcome to our newest member, hilda75
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
